Innoviva (INVA) Other Non-Current Liabilities (2014 - 2026)
Innoviva (INVA) posted Other Non-Current Liabilities of $69.1 million for Q1 2026, up 21.21% on a QoQ basis from $57.0 million in Q4 2025, and up 485.92% year-over-year from $11.8 million in Q1 2025.
Innoviva (INVA) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Innoviva's Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $69.1 million for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 485.92% year-over-year to $69.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.1 million (up 485.92% YoY) and the FY2025 annual result came in at $57.0 million, down 11.3% from the prior year.
- Other Non-Current Liabilities was $69.1 million for Q1 2026 at Innoviva, up from $57.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $78.4 million in Q3 2022 and bottomed at $1.1 million in Q3 2024.
- A 5-year average of $58.8 million and a median of $68.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 560050.0% — and 2024, when it sank 98.43%.
- Innoviva's Other Non-Current Liabilities stood at $67.9 million in 2022, then grew by 5.77% to $71.9 million in 2023, then declined by 10.57% to $64.3 million in 2024, then slipped by 11.3% to $57.0 million in 2025, then advanced by 21.21% to $69.1 million in 2026.
- Business Quant data shows INVA's Other Non-Current Liabilities at $69.1 million in Q1 2026, $57.0 million in Q4 2025, and $55.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.10 Mn |
| Dec 31, 2025 | 57.01 Mn |
| Sep 30, 2025 | 55.88 Mn |
| Jun 30, 2025 | 55.15 Mn |
| Mar 31, 2025 | 11.79 Mn |
| Dec 31, 2024 | 64.28 Mn |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 72.07 Mn |
| Mar 31, 2024 | 70.06 Mn |
| Dec 31, 2023 | 71.87 Mn |
| Sep 30, 2023 | 68.69 Mn |
| Jun 30, 2023 | 68.58 Mn |
| Mar 31, 2023 | 70.13 Mn |
| Dec 31, 2022 | 67.95 Mn |
| Sep 30, 2022 | 78.42 Mn |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | 45,000.00 |
| Mar 31, 2021 | 77,000.00 |
| Dec 31, 2020 | 106,000.00 |
| Sep 30, 2020 | 136,000.00 |